EP1017279A4 - Methods for regulating trka expression - Google Patents

Methods for regulating trka expression

Info

Publication number: EP1017279A4
Authority: EP; European Patent Office
Prior art keywords: regulating; methods; trka expression; trka; expression
Prior art date: 1997-09-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP98947151A

Other languages

German (de)

French (fr)

Other versions

EP1017279A1 (en

Inventor

Henry Uhlman Bryant

Robert Frank Santerre

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-23

Filing date

1998-09-18

Publication date

2002-07-31

1998-09-18 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2000-07-12 Publication of EP1017279A1 publication Critical patent/EP1017279A1/en

2002-07-31 Publication of EP1017279A4 publication Critical patent/EP1017279A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP98947151A 1997-09-23 1998-09-18 Methods for regulating trka expression Withdrawn EP1017279A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5961797P	1997-09-23	1997-09-23
US59617P		1997-09-23
PCT/US1998/019558 WO1999015016A1 (en)	1997-09-23	1998-09-18	Methods for regulating trka expression

Publications (2)

Publication Number	Publication Date
EP1017279A1 EP1017279A1 (en)	2000-07-12
EP1017279A4 true EP1017279A4 (en)	2002-07-31

Family

ID=22024123

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP98947151A Withdrawn EP1017279A4 (en)	1997-09-23	1998-09-18	Methods for regulating trka expression

Country Status (7)

Country	Link
US (1)	US5990129A (en)
EP (1)	EP1017279A4 (en)
JP (1)	JP2001516770A (en)
AU (1)	AU9399798A (en)
CA (1)	CA2304114A1 (en)
WO (1)	WO1999015016A1 (en)
ZA (1)	ZA988637B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI303990B (en)	2000-10-17	2008-12-11	Pfizer Prod Inc	New use of estrogen agonists/antagonists for improving vascular health
US8911734B2 (en)	2010-12-01	2014-12-16	Alderbio Holdings Llc	Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en)	2010-12-01	2015-06-30	Alderbio Holdings Llc	Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en)	2010-12-01	2015-07-14	Alderbio Holdings Llc	Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en)	2010-12-01	2022-01-04	H. Lundbeck A/S	High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en)	2010-12-01	2018-02-06	Alderbio Holdings Llc	Anti-NGF compositions and use thereof
US9539324B2 (en)	2010-12-01	2017-01-10	Alderbio Holdings, Llc	Methods of preventing inflammation and treating pain using anti-NGF compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0659418A1 (en) *	1993-12-21	1995-06-28	Eli Lilly And Company	2-Phenyl-3-azoylbenzothiophene for treating Alzheimer's disease
EP0663209A2 (en) *	1993-12-01	1995-07-19	Eli Lilly And Company	Medicament for inhibiting the effects of amyloidogenic proteins
US5504094A (en) *	1994-10-20	1996-04-02	Eli Lilly And Company	Use of bengothiophenls to treat pain due to an excess of neuropeptide y
US5512296A (en) *	1994-08-22	1996-04-30	Eli Lilly And Company	Methods for inhibiting neuronal damage
EP0716854A2 (en) *	1994-10-20	1996-06-19	Eli Lilly And Company	Compositions for inhibiting neuropeptide y receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) *	1988-10-31	1995-03-07	Endorecherche Inc.	Anti-estrogenic compounds and compositions
AU1442592A (en) *	1991-02-20	1992-09-15	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
JP3157882B2 (en) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	New benzothiophene derivatives
US5482949A (en) *	1993-03-19	1996-01-09	Eli Lilly And Company	Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) *	1993-06-21	1995-08-29	Eli Lilly And Company	Method for screening anti-osteoporosis agents
US5441947A (en) *	1993-08-25	1995-08-15	Eli Lilly And Company	Methods of inhibiting vascular restenosis
US6417198B1 (en) *	1993-12-21	2002-07-09	Eli Lilly And Company	Methods of inhibiting CNS problems in post-menopausal women
CA2143143A1 (en) *	1994-03-08	1995-09-09	Toshihiko Tanaka	3-phenylpyrrolidine derivatives
US5434166A (en) *	1994-08-22	1995-07-18	Eli Lilly And Company	Methods of inhibiting demyelinating and desmyelinating diseases
US5494929A (en) *	1995-01-12	1996-02-27	Eli Lilly And Company	Methods of inhibiting growth hormone effects
JPH08253417A (en) *	1995-02-28	1996-10-01	Eli Lilly & Co	Pharmaceutical preparation for suppressing estrogen positive tumor of brain or cns
US6545027B1 (en) *	1995-06-07	2003-04-08	Eli Lilly And Company	Methods of modulating NF-kB transcription factor
EP0747051B1 (en) *	1995-06-07	2002-07-24	Eli Lilly And Company	Treatment of diseases by inducing BEF-1 transcription factor

1998
- 1998-09-09 US US09/150,271 patent/US5990129A/en not_active Expired - Fee Related
- 1998-09-18 WO PCT/US1998/019558 patent/WO1999015016A1/en not_active Application Discontinuation
- 1998-09-18 CA CA002304114A patent/CA2304114A1/en not_active Abandoned
- 1998-09-18 EP EP98947151A patent/EP1017279A4/en not_active Withdrawn
- 1998-09-18 JP JP2000512411A patent/JP2001516770A/en not_active Withdrawn
- 1998-09-18 AU AU93997/98A patent/AU9399798A/en not_active Abandoned
- 1998-09-21 ZA ZA9808637A patent/ZA988637B/en unknown

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0663209A2 (en) *	1993-12-01	1995-07-19	Eli Lilly And Company	Medicament for inhibiting the effects of amyloidogenic proteins
EP0659418A1 (en) *	1993-12-21	1995-06-28	Eli Lilly And Company	2-Phenyl-3-azoylbenzothiophene for treating Alzheimer's disease
US5512296A (en) *	1994-08-22	1996-04-30	Eli Lilly And Company	Methods for inhibiting neuronal damage
US5504094A (en) *	1994-10-20	1996-04-02	Eli Lilly And Company	Use of bengothiophenls to treat pain due to an excess of neuropeptide y
EP0716854A2 (en) *	1994-10-20	1996-06-19	Eli Lilly And Company	Compositions for inhibiting neuropeptide y receptors
US5567715A (en) *	1994-10-20	1996-10-22	Eli Lilly And Company	Methods of treating depression by inhibiting physiological conditions associated with an excess of neuropeptide Y
US5567714A (en) *	1994-10-20	1996-10-22	Eli Lilly And Company	Methods of treating obesity by inhibiting physiological conditions associated with an excess of neuropeptide Y
US5576337A (en) *	1994-10-20	1996-11-19	Eli Lilly And Company	Method of treating anxiety by inhibiting physiological conditions associated with an excess of neuropeptide Y

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IBANEZ C F: "Neurotrophic factors: from structure-function studies to designing effective therapeutics", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 6, June 1995 (1995-06-01), pages 217 - 227, XP004207169, ISSN: 0167-7799 *
See also references of WO9915016A1 *

Also Published As

Publication number	Publication date
US5990129A (en)	1999-11-23
JP2001516770A (en)	2001-10-02
EP1017279A1 (en)	2000-07-12
WO1999015016A1 (en)	1999-04-01
ZA988637B (en)	2000-03-22
CA2304114A1 (en)	1999-04-01
AU9399798A (en)	1999-04-12

Publication	Publication Date	Title
GB2329924B (en)	2001-07-04	Single control system for top-down-bottom-up shades
HUP0200558A3 (en)	2004-11-29	Expression system for factor viii
GB9606791D0 (en)	1996-06-05	Control interface
HUP9904616A3 (en)	2001-02-28	Meiosis regulating cholestane-derivatives
TW342707U (en)	1998-10-11	Incubator
GB9720039D0 (en)	1997-11-19	Control
GB9624486D0 (en)	1997-01-15	Control means
ZA9811537B (en)	2000-06-27	Methods for regulating phagocytosis.
TW365161U (en)	1999-07-21	Incubator
TW397184U (en)	2000-07-01	Selectively enabling lighter
EP1017279A4 (en)	2002-07-31	Methods for regulating trka expression
GB9720430D0 (en)	1997-11-26	Control method
HUP0104032A3 (en)	2003-09-29	Novel system for regulating transgene expression
GB2308509B (en)	2000-05-31	Services-connections for trailer-vehicles
GB2308393B (en)	1999-10-13	Windshelter for sun-bathing
GB2314014B (en)	1998-04-29	Closure-arrangements for loose-covers
GB2298174B (en)	1998-07-29	Services-connections for trailer-vehicles
TW348859U (en)	1998-12-21	Improvement for spectacles structure
HU0400360D0 (en)	2004-05-28	Set for autolog transplantation
HRP970190B1 (en)	2000-06-30	Photovoltaic apparatus for central control
HU9700613D0 (en)	1997-05-28	Block for using whirl-energie
KR0111665Y1 (en)	1997-12-22	Stem for gas-vessel
AP9600848A0 (en)	1996-10-31	Ther peuti amid s
CA80937S (en)	1997-05-30	Chair for cable-lifts
TW352160U (en)	1999-02-01	Structure improvement for spectacle

Legal Events

Date	Code	Title	Description
2000-05-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-07-12	17P	Request for examination filed	Effective date: 20000321
2000-07-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE
2002-07-31	A4	Supplementary search report drawn up and despatched	Effective date: 20020619
2002-07-31	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE
2002-07-31	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/35 A
2003-02-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2003-04-02	18D	Application deemed to be withdrawn	Effective date: 20020910
2003-04-09	R18D	Application deemed to be withdrawn (corrected)	Effective date: 20020907